Marinus Pharmaceuticals Inc (STU:61Y)
€ 0.292 0.076 (35.19%) Market Cap: 19.67 Mil Enterprise Value: 32.91 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Marinus Pharmaceuticals, Inc. - Special Call Transcript

Dec 09, 2019 / 12:15PM GMT
Release Date Price: €4.52 (-7.38%)
Lisa M. Caperelli
Marinus Pharmaceuticals, Inc. - Executive Director of Investor & Strategic Relations

Thank you, everyone. So this morning, we're going to have our newly appointed Chief Medical Officer, Dr. Joseph Hulihan, take us through the use of Ganaxolone IV in refractory status epilepticus.

Specifically, he's going to speak to the new Phase II data that was presented here this weekend at AES, as well as our plans for our Phase III clinical trial.

Joe will then turn the presentation over to TJ Lyons. TJ is our VP of Business Development and Commercial Opportunities. And TJ will take us through the market opportunity for status epilepticus and refractory status epilepticus.

After their presentations, I ask that you hold all of your questions until the end of their presentations, at which time they will be available for the Q&A and joining them will also be Dr. Michael Rogawski from UC Davis as well as Dr. Eugene Ramsay from the Ochsner Comprehensive Epilepsy Center, who is also an investigator in our Phase II clinical study.

And quickly, before we begin

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot